SK bioscience CEO Jaeyong Ahn (left) and Doherty Institute director Professor Sharon Lewin at the signing ceremony. Credit: SK bioscience.

SK bioscience and Australia’s Peter Doherty Institute for Infection and Immunity have signed a research collaboration deal for the development of a next-generation influenza vaccine.

The company and the research institute will collaborate in further research on influenza biology, antivirals and vaccines.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The programme will include testing anti-influenza compounds to identify new antivirals, a new influenza vaccine platform development and building vaccine capacity in low and middle-income countries.

SK bioscience CEO Jaeyong Ahn said: “We expect a synergy combined with our capability in developing the world´s first quadrivalent cell culture-based influenza vaccine and the infrastructure of the Doherty Institute, a leading research institution on global infectious diseases.

“We will strengthen global partnerships with various organisations and continuously expand cooperative areas to establish a response system against infectious disease pandemics in the world.”

The company also intends to establish a proactive response system against influenza, contributing to public health on a global scale.

Doherty Institute director Professor Sharon Lewin stated: “Our organisations joining forces through our influenza projects is a significant milestone in our shared commitment to tackling infectious diseases and promoting public health.

“By collaborating with SK bioscience, we will strengthen our ability to respond to global challenges through exchanging knowledge and fostering innovation.

“Together, we will make a lasting impact in the prevention and treatment of infectious diseases, like influenza, around the world.”